Related Experiment Video
Updated: May 6, 2026
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies
Federica Barbieri1, Manuela Albertelli1, Federica Grillo2
1Department of Internal Medicine and Center of Excellence for Biomedical Research (CEBR), University of Genova, viale Benedetto XV, 2-16132 Genova, Italy.
Abstract:
Neuroendocrine tumors (NETs) are heterogeneous neoplasms with respect to molecular characteristics and clinical outcome. Although slow-growing, NETs are often late diagnosed, already showing invasion of adjacent tissues and metastases. Precise knowledge of NET biological and molecular features has opened the door to the identification of novel pharmacological targets. Therapeutic options include somatostatin analogs, alone or in combination with interferon-α, multi-targeted tyrosine kinase inhibitors (e.g. sunitinib) or mammalian target of rapamycin (mTOR) inhibitors (e.g. everolimus). Antiangiogenic approaches and anti insulin-like growth factor receptor (IGFR) compounds have been also proposed as combination therapies with the aforementioned compounds. This review will focus on recent studies that have improved therapeutic strategies in NETs, discussing management challenges such as drug resistance development as well as focusing on the need for predictive biomarkers to design distinct drug combinations and optimize pharmacological control.
Insights
Neuroendocrine tumors (NETs) are complex, often diagnosed late. Recent advances offer new therapeutic targets and drug combinations for improved NET management and overcoming resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Neuroendocrine tumors (NETs) are heterogeneous neoplasms with variable clinical outcomes.
- NETs are often diagnosed at advanced stages, with invasion and metastasis.
- Understanding NET molecular features is key to identifying novel therapeutic targets.
Purpose of the Study:
- To review recent studies on improved therapeutic strategies for NETs.
- To discuss challenges in NET management, including drug resistance.
- To highlight the need for predictive biomarkers in optimizing NET treatment.
Main Methods:
- Review of recent scientific literature on NET therapeutics.
- Analysis of current and emerging pharmacological targets.
- Discussion of clinical management challenges and biomarker development.
Main Results:
- Established therapies include somatostatin analogs, interferon-α, tyrosine kinase inhibitors (e.g., sunitinib), and mTOR inhibitors (e.g., everolimus).
- Emerging strategies involve antiangiogenic and anti-IGFR compounds, often in combination therapies.
- Drug resistance and the need for predictive biomarkers are significant management challenges.
Conclusions:
- Advances in understanding NET biology have led to novel therapeutic targets and improved treatment strategies.
- Optimizing NET treatment requires addressing drug resistance and developing predictive biomarkers for personalized therapy.
- Future research should focus on combination therapies and biomarker-driven approaches for better pharmacological control.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:27Tumor Immunotherapy
02:38Mitogens and the Cell Cycle
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...